{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-23-000121","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2023-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.920494+00:00","generated_at":"2026-06-10T08:21:52.285244+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xeris exchanges $32M of 5% 2025 notes for $33.6M of 8% 2028 notes; extends debt maturity","bullets":["Exchanged $31,975,000 of 5% convertible notes due 2025 for $33,574,000 of 8% notes due July 2028.","Conversion price unchanged at ~$3.06 per share (~68% premium to Sept 26 closing price).","Only ~$15.2M of original 2025 notes remain; no other debt due until 2027.","Notes are senior unsecured; interest payable semi-annually starting Jan 15, 2024.","Redeemable after July 20, 2026 if stock exceeds 130% of conversion price."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-23-000121","json":"https://secwatch.observer/filing/0001867096-23-000121.json","markdown":"https://secwatch.observer/filing/0001867096-23-000121.md","text":"https://secwatch.observer/filing/0001867096-23-000121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000121/0001867096-23-000121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000121/xers-20230926.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:21:52.285244+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5bb2a5d67852d3cf13af981f3fce81f6122c0937","claim":"Xeris Biopharma Holdings, Inc. entered into Exchange Agreements with certain holders of the Guarantor's outstanding 5.00% Convertible Senior Notes due 2025 valued at $31,975,000 in aggregate principal amount of the Existing Notes for $33,574,000 in aggregate princip (effective 2023-09-26).","evidence_excerpt":"On September 26, 2023, Xeris Biopharma Holdings, Inc., a Delaware corporation (the “ Company ”), and Xeris Pharmaceuticals, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (the “ Guarantor ”), entered into separate, privately negotiated exchange agreements (the “ Exchange Agreements ”) with certain holders of the Guarantor’s outstanding 5.00% Convertible Senior Notes due 2025 (the “ Existing Notes ”), pursuant to which the Company will exchange $31,975,000 in aggregate principal amount of the Existing Notes for $33,574,000 in aggregate principal amount of the Company’s new 8.00% Convertible Senior Notes due 2028 (the “ New Notes ”) (the “ Exchange Transactions ”), in each case, pursuant to the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended (the “ Securities Act ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000121/0001867096-23-000121-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"certain holders of the Guarantor's outstanding 5.00% Convertible Senior Notes due 2025"},{"label":"Value","value":"$31,975,000 in aggregate principal amount of the Existing Notes for $33,574,000 in aggregate princip"},{"label":"Effective","value":"2023-09-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}